Cellectar Biosc (CLRB) Stock Price, Quote & News

Company Profile

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort,...

Industry: Biotechnology

Sector: Healthcare

Phone: 608 441 8120

Website: www.cellectar.com

Address:

100 Campus Drive, Florham Park, United States

Zergg Dec. 24 at 7:23 PM

$CLRB we’re fine, i won’t be worried until mid q2 if nothing happens by then.

0 · Reply

revuelto Dec. 24 at 3:58 PM

$CLRB algos gonna algo 🤷‍♂️✌️

0 · Reply

RunningTime2025 Dec. 24 at 3:42 PM

$CLRB no signs of return, maybe it will heading down until delisted.

1 · Reply

szcyxzh Dec. 24 at 1:14 PM

$CLRB Bagholder and negative IQ loser dress up like insiders, giving "insider" info. and claim not financial advice. Think about before you walk out of the hospital door, your doctor telling you "this is not a medical advice." Meanwhile, the spammer "EvenBetter99" keeps spamming to seduce low IQ gamblers. To quote Mr. President: what a shithole this ticker is. (insert laughing emoji)

0 · Reply

KilimanjaroCap Dec. 24 at 11:40 AM

$CLRB Market attention is shifting toward whether measurable traction replaces episodic catalyst-driven interest. Inconsistent delivery may prolong volatility.

1 · Reply

ch0182 Dec. 23 at 5:51 PM

$CLRB how much cash do they have? I’m thinking about jumping in but I’m worried about dilution.

3 · Reply

EvenBetter99 Dec. 23 at 7:51 AM

$CLRB

0 · Reply

higgggghhhher Dec. 23 at 4:03 AM

$CLRB https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

RadioIsotope25 Dec. 23 at 1:38 AM

$CLRB Industry news https://scr.zacks.com/news/news-details/2025/RADX-Interim-Readout-Achieves-92-Concordance-article/default.aspx

0 · Reply

JTSawyer66 Dec. 22 at 4:51 PM

$CLRB Do we know the total float?

1 · Reply

Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

Nov 13, 2025, 3:41 PM EST - 5 weeks ago

Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:20 AM EST - 6 weeks ago

Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 14, 2025, 8:30 AM EDT - 2 months ago

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

Sep 11, 2025, 8:05 AM EDT - 3 months ago

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225

Sep 9, 2025, 8:05 AM EDT - 3 months ago

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Sep 5, 2025, 8:45 AM EDT - 3 months ago

Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September

Sep 3, 2025, 8:05 AM EDT - 4 months ago

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research

Aug 27, 2025, 8:05 AM EDT - 4 months ago

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Aug 14, 2025, 12:25 PM EDT - 4 months ago

Cellectar Biosciences, Inc. (CLRB) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:19 AM EDT - 4 months ago

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 7, 2025, 8:05 AM EDT - 5 months ago

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

Jul 2, 2025, 4:15 PM EDT - 6 months ago

Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

Jul 1, 2025, 9:25 AM EDT - 6 months ago

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

Jun 26, 2025, 8:05 AM EDT - 6 months ago

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Jun 24, 2025, 8:30 AM EDT - 6 months ago

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)

Jun 18, 2025, 4:30 PM EDT - 6 months ago

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split

$Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma$

Jun 11, 2025, 8:05 AM EDT - 7 months ago

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma

Jun 5, 2025, 9:00 AM EDT - 7 months ago

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules

Jun 4, 2025, 8:05 AM EDT - 7 months ago

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)

May 13, 2025, 2:17 PM EDT - 8 months ago

Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 8 months ago

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 7, 2025, 8:05 AM EDT - 8 months ago

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

Apr 30, 2025, 8:05 AM EDT - 8 months ago

Cellectar Announces Plan to Explore Strategic Alternatives

Mar 13, 2025, 12:41 PM EDT - 10 months ago

Cellectar Biosciences Inc. (CLRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:05 AM EDT - 10 months ago

Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

Mar 5, 2025, 8:05 AM EST - 10 months ago

Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

Feb 5, 2025, 8:05 AM EST - 11 months ago

Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 12, 2025, 6:00 PM EST - 1 year ago

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Dec 11, 2024, 11:25 AM EST - 1 year ago

Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options

Dec 10, 2024, 5:00 PM EST - 1 year ago

Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring

Nov 21, 2024, 8:00 AM EST - 1 year ago

NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)

Nov 18, 2024, 10:59 AM EST - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript

Nov 18, 2024, 7:05 AM EST - 1 year ago

Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225

Nov 12, 2024, 8:05 AM EST - 1 year ago

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer

Nov 11, 2024, 4:05 PM EST - 1 year ago

Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024

Nov 7, 2024, 6:40 AM EST - 1 year ago

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024

Nov 1, 2024, 5:00 PM EDT - 1 year ago

Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q

Aug 26, 2024, 6:40 AM EDT - 1 year ago

Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq

Aug 13, 2024, 1:25 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update

Aug 8, 2024, 5:15 PM EDT - 1 year ago

UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024

Jul 24, 2024, 3:22 PM EDT - 1 year ago

Cellectar Biosciences, Inc. (CLRB) KOL and Analyst Day Call Transcript

Jul 23, 2024, 3:09 PM EDT - 1 year ago

Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones

Jul 23, 2024, 10:49 AM EDT - 1 year ago

Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study

Jul 23, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months

Jul 22, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million

Jun 27, 2024, 6:40 AM EDT - 1 year ago

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape

Zergg Dec. 24 at 7:23 PM

$CLRB we’re fine, i won’t be worried until mid q2 if nothing happens by then.

0 · Reply

revuelto Dec. 24 at 3:58 PM

$CLRB algos gonna algo 🤷‍♂️✌️

0 · Reply

RunningTime2025 Dec. 24 at 3:42 PM

$CLRB no signs of return, maybe it will heading down until delisted.

1 · Reply

szcyxzh Dec. 24 at 1:14 PM

0 · Reply

KilimanjaroCap Dec. 24 at 11:40 AM

$CLRB Market attention is shifting toward whether measurable traction replaces episodic catalyst-driven interest. Inconsistent delivery may prolong volatility.

1 · Reply

ch0182 Dec. 23 at 5:51 PM

$CLRB how much cash do they have? I’m thinking about jumping in but I’m worried about dilution.

3 · Reply

EvenBetter99 Dec. 23 at 7:51 AM

$CLRB

0 · Reply

higgggghhhher Dec. 23 at 4:03 AM

$CLRB https://www.statnews.com/2025/12/04/fda-considers-single-clinical-trial-for-new-product-approvals/

0 · Reply

RadioIsotope25 Dec. 23 at 1:38 AM

$CLRB Industry news https://scr.zacks.com/news/news-details/2025/RADX-Interim-Readout-Achieves-92-Concordance-article/default.aspx

0 · Reply

JTSawyer66 Dec. 22 at 4:51 PM

$CLRB Do we know the total float?

1 · Reply

szcyxzh Dec. 22 at 2:18 PM

$CLRB same spammers, different people losing their money and mind here. So: Do watch out these spammers who want to suck more low IQ ppl into the hell they are enduring. BTW, I block these negative IQ lowlifes so that they will continue to buy (insert the rolling on the floor laughing with tears emoji).

0 · Reply

EvenBetter99 Dec. 21 at 11:59 AM

$CLRB stockprice is poised for a breakout. Only one indication brings this over USD 1 B marketcap in a nutshell. Every other indication will add easily + 1 B marketcap. This only with Iopofosine WM Phase 3 and MM, pHG Phase 2. The value of their PDC Platform is also not included yet. TNBC or Pancreatic are very very huge market (USD 10 B + each). 🚀🚀🚀🚀🚀🚀

0 · Reply

Zergg Dec. 20 at 3:25 PM

$CLRB i’m quite convinced on this one guys. Obviously there is risk, but the data and stars seem to be aligned

1 · Reply

Altairus Dec. 20 at 7:14 AM

$CLRB https://clinicaltrials.gov/study/NCT02952508

0 · Reply

Altairus Dec. 20 at 2:47 AM

$CLRB CLRB - Iopofosine I 131 single dose Phase 2 Results Expected (Phase 2) - Expected: 21/12/2025 https://catalystalert.io/company/CLRB

0 · Reply

szcyxzh Dec. 19 at 1:31 PM

$CLRB Breakout SOON, Gap Up SOON, JPM Conf. SOON, and Merry. C. to My Bagholder Comrades. When you team up with IQ negative losers, no sorry for your PL, where P is impossible. Let the CEO dilutes 1000%+ (100+% dilu + 1:10RS) again and K.O. ALL "investors" for the final brutal reality about an outdated tech from U of Wiscon. Go Altman for the new AGE!!!

1 · Reply

revuelto Dec. 19 at 11:30 AM

$CLRB either today or around the jpm conference in a few weeks, it could announce an acquisition or partnership news.…until then, wishing everyone the best. Merry Christmas and a very Happy New Year 🎉✌️

0 · Reply

revuelto Dec. 18 at 8:12 PM

$CLRB aside from a major gap up, could this deliver an sprb style move? Absolutely, but management needs to stop fumbling and execute decisively and fast….Jim Caruso, with your industry experience is that really too much to ask? Make it happen! ✌️

0 · Reply

CodeSurge Dec. 18 at 6:30 PM

$CLRB

0 · Reply

EvenBetter99 Dec. 18 at 5:44 PM

$CLRB modest 5000 3rd line patients EU and US cost: 100k revenue: 500'000'000 multiply rev with 20: 10 B Share Price up: 600 times 🚀🚀🚀🚀🚀🚀 what is yout calculation?

1 · Reply

EvenBetter99 Dec. 18 at 4:24 PM

$CLRB breathe and dont resist - just too good to be true

0 · Reply

revuelto Dec. 18 at 1:05 AM

$CLRB one more post before the incoming gap up here… sanofi, novartis, bms would love to scoop this up on the cheap with everything they’ve got…don’t miss the forest for the trees✌️🥳

0 · Reply

Market Cap	16.84M
Revenue (ttm)	0.00
Net Income (ttm)	-44.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	3,765,327
Avg Vol	14,877,256
Day's Range	N/A - N/A
Shares Out	46.08M
Stochastic %K	31%
Beta	0.52
Analysts	Sell
Price Target	$4.00